Page 1

OptiScan Imaging Limited ASX Announcement 27 October 2021 ABN 81 077 771 987 APPENDIX 4C QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 30 SEPTEMBER 2021 - Melbourne , Australia , 27 October 2021 : Optiscan Imaging Limited ( ASX : OIL ) ( Optiscan or the Company ) , a leader in medical technology using confocal laser endomicroscopy , is pleased to release its Appendix 4C Quarterly Cashflow report and business update for the quarter ended 30 September 2021 ( Quarter ) . All financial results are in Australian dollars and are unaudited . Highlights for the Quarter • First Australian sale of a FIVE2 system to Swinburne University as part of a Victorian Government MedTechVic initiative . • University of Melbourne's Melbourne Dental School ( MDS ) trial to improve screening , diagnosis and treatment of oral cancer progressed with 110 imaging sets completed by the end of the Quarter and 120 sets by 20 October . • • • • • • Australia's 2nd highest ranked dental school , the University of Adelaide Dental School , received final approval for its " Proof of Concept Study : A diagnostic tool to detect Oral Squamous Cell Carcinoma ” . Progress continues in preparing for the application for FDA approval for the InVivage ™ device for use in oral cancer screening and surgery in the United States . Completed imaging of 35 of 40 patients for stage three of the Breast Cancer Surgical Margin Assessment Trial . Increased sales pipeline for FIVE2 system with funding applications for purchases made and demonstrations conducted in Australia and North America . Orders from Carl Zeiss Meditec AG ( CZM ) for the CONVIVO device of approximately $ 175k for use in neurosurgery . Total Cash Flows of ( $ 844k ) for the Quarter with Cash Flows from Operating Activities of ( $ 935k ) for the Quarter ending 30 September 2021 . Developments Post End of Quarter • A leading Melbourne based medical research institution has received funding approval for a FIVE2 system and purchase documentation is being prepared . This will be the second Australian sale of a FIVE2 system this financial year . • Receipt of Optiscan's R & D Tax Incentive rebate for the 2020/21 financial year amounting to $ 770k . The R & D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5 % of eligible expenditure on research and development . Phone ( 613 ) 9538 3333 Website www.Optiscan.com 16 Miles Street , Mulgrave , VIC , 3170 Australia